Carla C Baan

List of Publications by Year in Descending Order

220 papers	6,019 citations	44 h-index	65 g-index
249 ext. papers	7,105 ext. citations	3.9 avg, IF	5.62 L-index

#	Paper	IF	Citations
220	Immune Subsets From Ficoll Density Gradient Separation in Kidney Transplant Recipients.. *Transplantation Direct*, **2022**, 8, e1319	2.3	0
219	A Population Pharmacokinetic Model of Whole-Blood and Intracellular Tacrolimus in Kidney Transplant Recipients.. *European Journal of Drug Metabolism and Pharmacokinetics*, **2022**, 1	2.7	0
218	Monitoring Intracellular Tacrolimus Concentrations And Its Relationship With Rejection In The Early Phase After Renal Transplantation. *Clinical Biochemistry*, **2021**,	3.5	1
217	The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. *Transplantation*, **2021**, 106,	1.8	17
216	Variations in DNA methylation and allograft rejection. *Current Opinion in Organ Transplantation*, **2021**, 26, 30-36	2.5	2
215	Chronic-active Antibody-mediated Rejection: To Belatacept or Not, That Is the HOT Question. *Transplantation*, **2021**, 105, 478-479	1.8	1
214	Ex Vivo Administration of Mesenchymal Stromal Cells in Kidney Grafts Against Ischemia-reperfusion Injury-Effective Delivery Without Kidney Function Improvement Posttransplant. *Transplantation*, **2021**, 105, 517-528	1.8	6
213	Mesenchymal stromal cell treatment of donor kidneys during ex vivo normothermic machine perfusion: A porcine renal autotransplantation study. *American Journal of Transplantation*, **2021**, 21, 2348-2359	8.7	12
212	Membrane particles from mesenchymal stromal cells reduce the expression of fibrotic markers on pulmonary cells. *PLoS ONE*, **2021**, 16, e0248415	3.7	0
211	Mesenchymal Stromal Cell Derived Membrane Particles Are Internalized by Macrophages and Endothelial Cells Through Receptor-Mediated Endocytosis and Phagocytosis. *Frontiers in Immunology*, **2021**, 12, 651109	8.4	2
210	Membrane Particles Derived From Adipose Tissue Mesenchymal Stromal Cells Improve Endothelial Cell Barrier Integrity. *Frontiers in Immunology*, **2021**, 12, 650522	8.4	2
209	The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant. *Nephrology Dialysis Transplantation*, **2021**, 36, 1761-1764	4.3	11
208	Pre-transplant donor-reactive IL-21 producing T cells as a tool to identify an increased risk for acute rejection. *Scientific Reports*, **2021**, 11, 12445	4.9	2
207	Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2021**, 54-55, 101756	2.5	1
206	A systematic review and meta-analysis of enzyme-linked immunosorbent spot (ELISPOT) assay for BK polyomavirus immune response monitoring after kidney transplantation. *Journal of Clinical Virology*, **2021**, 140, 104848	14.5	1
205	Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients. *British Journal of Clinical Pharmacology*, **2021**, 87, 1918-1929	3.8	6
204	Human kidney organoids produce functional renin. *Kidney International*, **2021**, 99, 134-147	9.9	12

203	Advanced Research Models to Study the Role of Endothelial Cells in Solid Organ Transplantation. *Frontiers in Immunology*, **2021**, 12, 607953	8.4	1
202	Circulating cell-free nucleosomes as biomarker for kidney transplant rejection: a pilot study. *Clinical Epigenetics*, **2021**, 13, 32	7.7	0
201	Donor-specific ELISPOT assay for predicting acute rejection and allograft function after kidney transplantation: A systematic review and meta-analysis. *Clinical Biochemistry*, **2021**, 94, 1-11	3.5	1
200	Identification of Predictive Markers for the Generation of Well-Differentiated Human Induced Pluripotent Stem Cell-Derived Kidney Organoids. *Stem Cells and Development*, **2021**, 30, 1103-1114	4.4	
199	Natural Antibodies and Alloreactive T Cells Long after Kidney Transplantation. *Journal of Transplantation*, **2021**, 2021, 7005080	2.3	
198	A comparison of two different analytical methods for donor-derived cell-free DNA quantification. *Clinical Biochemistry*, **2021**, 96, 82-84	3.5	
197	Improved Normothermic Machine Perfusion After Short Oxygenated Hypothermic Machine Perfusion of Ischemically Injured Porcine Kidneys. *Transplantation Direct*, **2021**, 7, e653	2.3	0
196	Molecular Analysis of Renal Allograft Biopsies: Where Do We Stand and Where Are We Going?. *Transplantation*, **2020**, 104, 2478-2486	1.8	5
195	Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection. *Frontiers in Immunology*, **2020**, 11, 1332	8.4	3
194	THE SMALL-MOLECULE BCL6-INHIBITOR 79-6 SUPPRESSES FOLLICULAR T HELPER CELL DIFFERENTIATION AND PLASMA BLAST FORMATION. *Transplantation*, **2020**, 104, S144-S144	1.8	
193	IMMUNOSUPPRESSION AFFECTS CIRCULATING FOLLICULAR REGULATORY T CELLS IN KIDNEY TRANSPLANT RECIPIENTS. *Transplantation*, **2020**, 104, S130-S130	1.8	
192	The Importance of Dosing, Timing, and (in)Activation of Adipose Tissue-Derived Mesenchymal Stromal Cells on Their Immunomodulatory Effects. *Stem Cells and Development*, **2020**, 29, 38-48	4.4	8
191	Costimulation Blockade in Kidney Transplant Recipients. *Drugs*, **2020**, 80, 33-46	12.1	13
190	Reparative effect of mesenchymal stromal cells on endothelial cells after hypoxic and inflammatory injury. *Stem Cell Research and Therapy*, **2020**, 11, 352	8.3	10
189	Immunosuppression Has Long-Lasting Effects on Circulating Follicular Regulatory T Cells in Kidney Transplant Recipients. *Frontiers in Immunology*, **2020**, 11, 1972	8.4	7
188	The Number of Donor-Specific IL-21 Producing Cells Before and After Transplantation Predicts Kidney Graft Rejection. *Frontiers in Immunology*, **2019**, 10, 748	8.4	18
187	Characterization of donor and recipient CD8+ tissue-resident memory T cells in transplant nephrectomies. *Scientific Reports*, **2019**, 9, 5984	4.9	23
186	Effects of Normothermic Machine Perfusion Conditions on Mesenchymal Stromal Cells. *Frontiers in Immunology*, **2019**, 10, 765	8.4	21

185	Current State of Renal Regenerative Therapies. *Transplantation*, **2019**, 103, 250-261	1.8	1
184	The role of follicular T helper cells in the humoral alloimmune response after clinical organ transplantation. *Hla*, **2019**, 94, 407-414	1.9	10
183	Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment **2019**, 7, 182		18
182	Mesenchymal Stromal Cells Are Retained in the Porcine Renal Cortex Independently of Their Metabolic State After Renal Intra-Arterial Infusion. *Stem Cells and Development*, **2019**, 28, 1224-1235	4.4	13
181	Early Immunological Effects of Ischemia-Reperfusion Injury: No Modulation by Ischemic Preconditioning in a Randomised Crossover Trial in Healthy Humans. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	3
180	Impact of low tacrolimus exposure and high tacrolimus intra-patient variability on the development of anti-HLA donor-specific antibodies in kidney transplant recipients. *Expert Review of Clinical Immunology*, **2019**, 15, 1323-1331	5.1	10
179	Inhibition of T Helper Cell Differentiation by Tacrolimus or Sirolimus Results in Reduced B-Cell Activation: Effects on T Follicular Helper Cells. *Transplantation Proceedings*, **2019**, 51, 3463-3473	1.1	10
178	An overview of T follicular cells in transplantation: spotlight on their clinical significance. *Expert Review of Clinical Immunology*, **2019**, 15, 1249-1262	5.1	3
177	Targeted Proteomic Analysis Detects Acute T Cell-Mediated Kidney Allograft Rejection in Belatacept-Treated Patients. *Therapeutic Drug Monitoring*, **2019**, 41, 243-248	3.2	1
176	Repairing and Regenerating Organs for Transplantation Has Become a Reality. *Transplantation*, **2019**, 103, 224-226	1.8	1
175	Nanoparticle Release by Extended Criteria Donor Kidneys During Normothermic Machine Perfusion. *Transplantation*, **2019**, 103, e110-e111	1.8	7
174	Immunomics of Renal Allograft Acute T Cell-Mediated Rejection Biopsies of Tacrolimus- and Belatacept-Treated Patients. *Transplantation Direct*, **2019**, 5, e418	2.3	11
173	A Pilot Study of Postoperative Animal Welfare as a Guidance Tool in the Development of a Kidney Autotransplantation Model With Extended Warm Ischemia. *Transplantation Direct*, **2019**, 5, e495	2.3	5
172	The Effects of an IL-21 Receptor Antagonist on the Alloimmune Response in a Humanized Mouse Skin Transplant Model. *Transplantation*, **2019**, 103, 2065-2074	1.8	6
171	Highly sensitive and rapid determination of tacrolimus in peripheral blood mononuclear cells by liquid chromatography-tandem mass spectrometry. *Biomedical Chromatography*, **2019**, 33, e4416	1.7	12
170	Immunomodulation By Therapeutic Mesenchymal Stromal Cells (MSC) Is Triggered Through Phagocytosis of MSC By Monocytic Cells. *Stem Cells*, **2018**, 36, 602-615	5.8	231
169	Improved Glucose Tolerance in a Kidney Transplant Recipient With Type 2 Diabetes Mellitus After Switching From Tacrolimus To Belatacept: A Case Report and Review of Potential Mechanisms. *Transplantation Direct*, **2018**, 4, e350	2.3	5
168	In Case you Missed It-Basic Science Advances in Transplantation 2017. *Transplantation*, **2018**, 102, 932-934	4.8	1

167	Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation. *Clinical Pharmacokinetics*, **2018**, 57, 191-207	6.2	41
166	Analysis of NFATc1 amplification in T cells for pharmacodynamic monitoring of tacrolimus in kidney transplant recipients. *PLoS ONE*, **2018**, 13, e0201113	3.7	7
165	Response: Commentary: Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation. *Frontiers in Immunology*, **2018**, 9, 466	8.4	
164	Differentially methylated regions in T cells identify kidney transplant patients at risk for de novo skin cancer. *Clinical Epigenetics*, **2018**, 10, 81	7.7	11
163	The Efficacy of Rabbit Anti-Thymocyte Globulin for Acute Kidney Transplant Rejection in Patients Using Calcineurin Inhibitor and Mycophenolate Mofetil-Based Immunosuppressive Therapy. *Annals of Transplantation*, **2018**, 23, 577-590	1.4	2
162	Monocytic Cells Phagocytose Therapeutic Mesenchymal Stem Cells, which Induces Polarization, Relocation and Immune Regulation. *Transplantation*, **2018**, 102, S206	1.8	
161	Efficacy of Rabbit Anti-Thymocyte Globulin Therapy for Severe Acute Rejection in Kidney Transplant Patients using Calcineurin Inhibitor and Mycophenolate Mofetil based Immunosuppressive Therapy. *Transplantation*, **2018**, 102, S80	1.8	
160	Tissue-Resident Memory T Cells of Donor Origin are Short-Lived in Renal Allografts after Transplantation. *Transplantation*, **2018**, 102, S146	1.8	1
159	Renal Intra-Arterial Delivery of MSC to Ischemic Porcine Kidneys. *Transplantation*, **2018**, 102, S719	1.8	
158	Liquid Biopsies to Monitor Solid Organ Transplant Function: A Review of New Biomarkers. *Therapeutic Drug Monitoring*, **2018**, 40, 515-525	3.2	23
157	Renal Allograft Transcription Analysis Reveals Similar Signature of Acute T Cell Mediated Rejection in Patients Treated with Tacrolimus or Belatacept. *Transplantation*, **2018**, 102, S142	1.8	
156	Epigenetic changes in umbilical cord mesenchymal stromal cells upon stimulation and culture expansion. *Cytotherapy*, **2018**, 20, 919-929	4.8	16
155	A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation. *Transplantation*, **2017**, 101, 2571-2581	1.8	40
154	Aging of bone marrow- and umbilical cord-derived mesenchymal stromal cells during expansion. *Cytotherapy*, **2017**, 19, 798-807	4.8	47
153	Mesenchymal Stromal Cells as Anti-Inflammatory and Regenerative Mediators for Donor Kidneys During Normothermic Machine Perfusion. *Stem Cells and Development*, **2017**, 26, 1162-1170	4.4	30
152	Membrane particles generated from mesenchymal stromal cells modulate immune responses by selective targeting of pro-inflammatory monocytes. *Scientific Reports*, **2017**, 7, 12100	4.9	48
151	The Effect of Tacrolimus and Mycophenolic Acid on CD14+ Monocyte Activation and Function. *PLoS ONE*, **2017**, 12, e0170806	3.7	24
150	Differential T Cell Signaling Pathway Activation by Tacrolimus and Belatacept after Kidney Transplantation: Post Hoc Analysis of a Randomised-Controlled Trial. *Scientific Reports*, **2017**, 7, 15135	4.9	8

149	Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. *Expert Opinion on Drug Metabolism and Toxicology*, **2017**, 13, 1225-1236	5.5	69
148	Pharmacodynamic Monitoring of Tacrolimus-Based Immunosuppression in CD14+ Monocytes After Kidney Transplantation. *Therapeutic Drug Monitoring*, **2017**, 39, 463-471	3.2	4
147	pERK-dependent defective TCR-mediated activation of CD4 T cells in end-stage renal disease patients. *Immunity and Ageing*, **2017**, 14, 14	9.7	9
146	Cytokine treatment optimises the immunotherapeutic effects of umbilical cord-derived MSC for treatment of inflammatory liver disease. *Stem Cell Research and Therapy*, **2017**, 8, 140	8.3	53
145	Targeting the Monocyte-Macrophage Lineage in Solid Organ Transplantation. *Frontiers in Immunology*, **2017**, 8, 153	8.4	36
144	IL-21 Receptor Antagonist Inhibits Differentiation of B Cells toward Plasmablasts upon Alloantigen Stimulation. *Frontiers in Immunology*, **2017**, 8, 306	8.4	31
143	CD16+ Monocytes and Skewed Macrophage Polarization toward M2 Type Hallmark Heart Transplant Acute Cellular Rejection. *Frontiers in Immunology*, **2017**, 8, 346	8.4	20
142	Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation. *Frontiers in Immunology*, **2017**, 8, 641	8.4	20
141	Interferon-Gamma DNA Methylation Is Affected by Mycophenolic Acid but Not by Tacrolimus after T-Cell Activation. *Frontiers in Immunology*, **2017**, 8, 822	8.4	9
140	Inflammatory Conditions Dictate the Effect of Mesenchymal Stem or Stromal Cells on B Cell Function. *Frontiers in Immunology*, **2017**, 8, 1042	8.4	67
139	T-Cell Composition of the Lymph Node Is Associated with the Risk for Early Rejection after Renal Transplantation. *Frontiers in Immunology*, **2017**, 8, 1416	8.4	4
138	T Follicular Helper Cells As a New Target for Immunosuppressive Therapies. *Frontiers in Immunology* , **2017**, 8, 1510	8.4	30
137	End-Stage Renal Disease Causes Skewing in the TCR VβRepertoire Primarily within CD8 T Cell Subsets. *Frontiers in Immunology*, **2017**, 8, 1826	8.4	11
136	IL-1 and IL-6 Are Highly Expressed in RF+IgE+ Systemic Lupus Erythematous Subtype. *Journal of Immunology Research*, **2017**, 2017, 5096741	4.5	14
135	Adipose Tissue-Derived Mesenchymal Stem Cells Have a Heterogenic Cytokine Secretion Profile. *Stem Cells International*, **2017**, 2017, 4960831	5	23
134	Conversion to Once-Daily Tacrolimus Results in Increased p38MAPK Phosphorylation in T Lymphocytes of Kidney Transplant Recipients. *Therapeutic Drug Monitoring*, **2016**, 38, 280-4	3.2	5
133	"Bioengineered lungs" Best science paper in JHLT 2014-2015. *Journal of Heart and Lung Transplantation*, **2016**, 35, 544-6	5.8	
132	Effects of Freeze-Thawing and Intravenous Infusion on Mesenchymal Stromal Cell Gene Expression. *Stem Cells and Development*, **2016**, 25, 586-97	4.4	51

131	Clinical potential of DNA methylation in organ transplantation. *Journal of Heart and Lung Transplantation*, **2016**, 35, 843-50	5.8	17
130	Loss of CD28 on Peripheral T Cells Decreases the Risk for Early Acute Rejection after Kidney Transplantation. *PLoS ONE*, **2016**, 11, e0150826	3.7	26
129	The Biological Effects of IL-21 Signaling on B-Cell-Mediated Responses in Organ Transplantation. *Frontiers in Immunology*, **2016**, 7, 319	8.4	19
128	Down-Regulation of Surface CD28 under Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells. *PLoS ONE*, **2016**, 11, e0148604	3.7	21
127	An Acute Cellular Rejection With Detrimental Outcome Occurring Under Belatacept-Based Immunosuppressive Therapy: An Immunological Analysis. *Transplantation*, **2016**, 100, 1111-9	1.8	21
126	Inactivated Mesenchymal Stem Cells Maintain Immunomodulatory Capacity. *Stem Cells and Development*, **2016**, 25, 1342-54	4.4	82
125	Alemtuzumab as Antirejection Therapy: T Cell Repopulation and Cytokine Responsiveness. *Transplantation Direct*, **2016**, 2, e83	2.3	7
124	Targeting JAK/STAT Signaling to Prevent Rejection After Kidney Transplantation: A Reappraisal. *Transplantation*, **2016**, 100, 1833-9	1.8	19
123	Variations in DNA methylation of interferon gamma and programmed death 1 in allograft rejection after kidney transplantation. *Clinical Epigenetics*, **2016**, 8, 116	7.7	12
122	Efficacy of immunotherapy with mesenchymal stem cells in man: a systematic review. *Expert Review of Clinical Immunology*, **2015**, 11, 617-36	5.1	22
121	Allogeneic Mature Human Dendritic Cells Generate Superior Alloreactive Regulatory T Cells in the Presence of IL-15. *Journal of Immunology*, **2015**, 194, 5282-93	5.3	12
120	Interleukin-17-producing CD4(+) cells home to the graft early after human heart transplantation. *Journal of Heart and Lung Transplantation*, **2015**, 34, 933-40	5.8	16
119	Therapeutic Drug Monitoring of Belatacept in Kidney Transplantation. *Therapeutic Drug Monitoring*, **2015**, 37, 560-7	3.2	19
118	End stage renal disease patients have a skewed T cell receptor Vβ repertoire. *Immunity and Ageing*, **2015**, 12, 28	9.7	14
117	Thymus-Derived Regulatory T Cells Infiltrate the Cardiac Allograft Before Rejection. *Transplantation*, **2015**, 99, 1839-46	1.8	10
116	T cells Exhibit Reduced Signal Transducer and Activator of Transcription 5 Phosphorylation and Upregulated Coinhibitory Molecule Expression After Kidney Transplantation. *Transplantation*, **2015**, 99, 1995-2003	1.8	9
115	CD4+ CXCR5+ T cells in chronic HCV infection produce less IL-21, yet are efficient at supporting B cell responses. *Journal of Hepatology*, **2015**, 62, 303-10	13.4	41
114	Toward Development of iMesenchymal Stem Cells for Immunomodulatory Therapy. *Frontiers in Immunology*, **2015**, 6, 648	8.4	51

113	Pretransplant identification of acute rejection risk following kidney transplantation. *Transplant International*, **2014**, 27, 129-38	3	46
112	No evidence for circulating mesenchymal stem cells in patients with organ injury. *Stem Cells and Development*, **2014**, 23, 2328-35	4.4	56
111	Uremia-associated immunological aging is stably imprinted in the T-cell system and not reversed by kidney transplantation. *Transplant International*, **2014**, 27, 1272-84	3	42
110	T Follicular Helper Cells in Transplantation: The Target to Attenuate Antibody-Mediated Allogeneic Responses?. *Current Transplantation Reports*, **2014**, 1, 166-172	1.5	18
109	Human monocytes produce interferon-gamma upon stimulation with LPS. *Cytokine*, **2014**, 67, 7-12	4	36
108	Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus. *Transplantation*, **2014**, 97, 47-55	1.8	16
107	The impact of induction therapy on the homeostasis and function of regulatory T cells in kidney transplant patients. *Nephrology Dialysis Transplantation*, **2014**, 29, 1587-97	4.3	36
106	Update on controls for isolation and quantification methodology of extracellular vesicles derived from adipose tissue mesenchymal stem cells. *Frontiers in Immunology*, **2014**, 5, 525	8.4	58
105	Rotterdam: main port for organ transplantation research in the Netherlands. *Transplant Immunology*, **2014**, 31, 200-6	1.7	1
104	Limited efficacy of immunosuppressive drugs on CD8+ T cell-mediated and natural killer cell-mediated lysis of human renal tubular epithelial cells. *Transplantation*, **2014**, 97, 1110-8	1.8	11
103	Mesenchymal stromal cells for organ transplantation: different sources and unique characteristics?. *Current Opinion in Organ Transplantation*, **2014**, 19, 41-6	2.5	53
102	T-cell ageing in end-stage renal disease patients: Assessment and clinical relevance. *World Journal of Nephrology*, **2014**, 3, 268-76	3.6	25
101	Mesenchymal stem cells induce an inflammatory response after intravenous infusion. *Stem Cells and Development*, **2013**, 22, 2825-35	4.4	89
100	Culture expansion induces non-tumorigenic aneuploidy in adipose tissue-derived mesenchymal stromal cells. *Cytotherapy*, **2013**, 15, 1352-61	4.8	33
99	Genetic variants of FOXP3 influence graft survival in kidney transplant patients. *Human Immunology* , **2013**, 74, 751-7	2.3	13
98	Differential effects of activated human renal epithelial cells on T-cell migration. *PLoS ONE*, **2013**, 8, e64916	3.7	15
97	Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus. *Therapeutic Drug Monitoring*, **2013**, 35, 459-65	3.2	32
96	Effects of Hypoxia on the Immunomodulatory Properties of Adipose Tissue-Derived Mesenchymal Stem cells. *Frontiers in Immunology*, **2013**, 4, 203	8.4	81

95	The effect of rabbit antithymocyte globulin on human mesenchymal stem cells. *Transplant International*, **2013**, 26, 651-8	3	6
94	Kinetics of homeostatic proliferation and thymopoiesis after rATG induction therapy in kidney transplant patients. *Transplantation*, **2013**, 96, 904-13	1.8	29
93	Interaction between adipose tissue-derived mesenchymal stem cells and regulatory T-cells. *Cell Transplantation*, **2013**, 22, 41-54	4	48
92	Tacrolimus inhibits NF-Β activation in peripheral human T cells. *PLoS ONE*, **2013**, 8, e60784	3.7	35
91	A shift towards pro-inflammatory CD16+ monocyte subsets with preserved cytokine production potential after kidney transplantation. *PLoS ONE*, **2013**, 8, e70152	3.7	25
90	Human Bone Marrow- and Adipose Tissue-derived Mesenchymal Stromal Cells are Immunosuppressive and in a Humanized Allograft Rejection Model. *Journal of Stem Cell Research & Therapy*, **2013**, Suppl 6, 20780	1	29
89	Human Allogeneic Bone Marrow and Adipose Tissue Derived Mesenchymal Stromal Cells Induce CD8+ Cytotoxic T Cell Reactivity. *Journal of Stem Cell Research & Therapy*, **2013**, 3, 004	1	13
88	Mesenchymal stem cells derived from adipose tissue are not affected by renal disease. *Kidney International*, **2012**, 82, 748-58	9.9	48
87	Phosphospecific flow cytometry for pharmacodynamic drug monitoring: analysis of the JAK-STAT signaling pathway. *Clinica Chimica Acta*, **2012**, 413, 1398-405	6.2	20
86	Uremia causes premature ageing of the T cell compartment in end-stage renal disease patients. *Immunity and Ageing*, **2012**, 9, 19	9.7	68
85	Phospho-specific flow cytometry for pharmacodynamic monitoring of immunosuppressive therapy in transplantation. *Transplantation Research*, **2012**, 1, 20		11
84	On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantation. *Frontiers in Immunology*, **2012**, 3, 126	8.4	60
83	The impact of mesenchymal stem cell therapy in transplant rejection and tolerance. *Current Opinion in Organ Transplantation*, **2012**, 17, 355-61	2.5	29
82	FoxP3 T cells and the pathophysiologic effects of brain death and warm ischemia in donor kidneys. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 1481-9	6.9	4
81	No prominent role for terminal complement activation in the early myocardial reperfusion phase following cardiac surgery. *European Journal of Cardio-thoracic Surgery*, **2012**, 41, e117-25	3	10
80	Inhibitory effect of tacrolimus on p38 mitogen-activated protein kinase signaling in kidney transplant recipients measured by whole-blood phosphospecific flow cytometry. *Transplantation*, **2012**, 93, 1245-51	1.8	14
79	Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients. *Transplantation*, **2012**, 94, 465-72	1.8	15
78	How does auxiliary liver transplantation regulate alloreactivity in sensitized kidney transplant patients?. *Transplantation*, **2011**, 91, 823-4	1.8	7

77	Human mesenchymal stem cells are susceptible to lysis by CD8(+) T cells and NK cells. *Cell Transplantation*, **2011**, 20, 1547-59	4	83
76	Discontinuation of calcineurin inhibitors treatment allows the development of FOXP3+ regulatory T-cells in patients after kidney transplantation. *Clinical Transplantation*, **2011**, 25, 40-6	3.8	19
75	The calcineurin inhibitor tacrolimus allows the induction of functional CD4CD25 regulatory T cells by rabbit anti-thymocyte globulins. *Clinical and Experimental Immunology*, **2010**, 161, 364-77	6.2	16
74	iTregs by vitamins: commentary on 'retinoic acid attenuates acute heart rejection by increasing regulatory T cell and repressing differentiation of Th17 in the presence of TGF-β' *Transplant International*, **2010**, 23, 984-5	3	1
73	The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. *International Immunopharmacology*, **2010**, 10, 1496-500	5.8	183
72	Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). *Transplantation*, **2010**, 90, 124-6	1.8	57
71	Characterization of rabbit antithymocyte globulins-induced CD25+ regulatory T cells from cells of patients with end-stage renal disease. *Transplantation*, **2010**, 89, 655-66	1.8	16
70	Human adipose tissue-derived mesenchymal stem cells induce explosive T-cell proliferation. *Stem Cells and Development*, **2010**, 19, 1843-53	4.4	78
69	The Jak inhibitor CP-690,550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells. *American Journal of Transplantation*, **2010**, 10, 1785-95	8.7	52
68	The effect of rabbit anti-thymocyte globulin induction therapy on regulatory T cells in kidney transplant patients. *Nephrology Dialysis Transplantation*, **2009**, 24, 1635-44	4.3	45
67	Cell contact interaction between adipose-derived stromal cells and allo-activated T lymphocytes. *European Journal of Immunology*, **2009**, 39, 3436-46	6.1	45
66	Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation. *Transplant International*, **2009**, 22, 365-76	3	66
65	Monotherapy rapamycin allows an increase of CD4 CD25 FoxP3 T cells in renal recipients. *Transplant International*, **2009**, 22, 884-91	3	42
64	End-stage renal failure and regulatory activities of CD4+CD25bright+FoxP3+ T-cells. *Nephrology Dialysis Transplantation*, **2009**, 24, 1969-78	4.3	76
63	Regulatory T cells in alloreactivity after clinical heart transplantation. *Current Opinion in Organ Transplantation*, **2009**, 14, 577-82	2.5	13
62	The Authors' Reply: Mesenchymal Stem Cells and Immunosuppressive Drug Interactions. *Transplantation*, **2009**, 87, 1900-1901	1.8	
61	Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetil-treated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not. *Therapeutic Drug Monitoring*, **2009**, 31, 549-56	3.2	22
60	Generation of donor-specific regulatory T-cell function in kidney transplant patients. *Transplantation*, **2009**, 87, 376-83	1.8	21

59	Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. *Transplantation*, **2009**, 87, 896-906	1.8	85
58	The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients. *Transplantation*, **2009**, 87, 79-86	1.8	42
57	Deficient TNF-alpha and IFN-gamma production correlates with nondetectable donor-specific cytotoxicity after clinical kidney transplantation. *Transplantation*, **2009**, 87, 1451-4	1.8	8
56	Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. *Transplantation*, **2009**, 88, 614-9	1.8	58
55	Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells. *Transplantation*, **2009**, 87, 1062-8	1.8	67
54	Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients. *Transplantation*, **2009**, 88, 1002-9	1.8	33
53	Inadequate immune regulatory function of CD4+CD25bright+FoxP3+ T cells in heart transplant patients who experience acute cellular rejection. *Transplantation*, **2009**, 87, 1191-200	1.8	19
52	Functional analysis of CD4+ CD25bright T cells in kidney transplant patients: improving suppression of donor-directed responses after transplantation. *Clinical Transplantation*, **2008**, 22, 579-86	3.8	17
51	Hepatitis B vaccine-specific CD4(+) T cells can be detected and characterised at the single cell level: limited usefulness of dendritic cells as signal enhancers. *Journal of Immunological Methods*, **2008**, 330, 1-11	2.5	26
50	Regulatory T cells after organ transplantation: where does their action take place?. *Human Immunology*, **2008**, 69, 389-98	2.3	46
49	FOXP3 mRNA expression analysis in the peripheral blood and allograft of heart transplant patients. *Transplant Immunology*, **2008**, 18, 250-4	1.7	31
48	Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. *Transplantation*, **2008**, 86, 1283-91	1.8	79
47	Impact of immunosuppressive drugs on CD4+CD25+FOXP3+ regulatory T cells: does in vitro evidence translate to the clinical setting?. *Transplantation*, **2008**, 85, 783-9	1.8	79
46	After discontinuation of calcineurin inhibitors, tapering of mycophenolate mofetil further impairs donor-directed cytotoxicity. *Clinical Transplantation*, **2008**, 22, 129-35	3.8	6
45	Ficoll-separated mononuclear cells from sepsis patients are contaminated with granulocytes. *Intensive Care Medicine*, **2008**, 34, 912-6	14.5	16
44	Functional CD25(bright+) alloresponsive T cells in fully immunosuppressed renal allograft recipients. *Clinical Transplantation*, **2007**, 21, 63-71	3.8	20
43	Allosuppressive donor CD4+CD25+ regulatory T cells detach from the graft and circulate in recipients after liver transplantation. *Journal of Immunology*, **2007**, 178, 6066-72	5.3	37
42	Intrahepatic detection of FOXP3 gene expression after liver transplantation using minimally invasive aspiration biopsy. *Transplantation*, **2007**, 83, 819-23	1.8	23

41	Interleukin-21: an interleukin-2 dependent player in rejection processes. *Transplantation*, **2007**, 83, 1485-92	3.2	26
40	Intragraft FOXP3 mRNA expression reflects antidonor immune reactivity in cardiac allograft patients. *Transplantation*, **2007**, 83, 1477-84	1.8	45
39	Targeting the IL-15 pathway to prevent rejection after organ transplantation. *Transplantation Reviews*, **2006**, 20, 28-33	3.3	
38	The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response. *Circulation*, **2006**, 114, 1599-607	16.7	88
37	Donor-specific cytotoxic hyporesponsiveness associated with high interleukin-10 messenger RNA expression in cardiac allograft patients. *Journal of Heart and Lung Transplantation*, **2006**, 25, 955-64	5.8	5
36	The impact of transforming growth factor-beta1 gene polymorphism on end-stage renal failure after heart transplantation. *Transplantation*, **2006**, 82, 1744-8	1.8	31
35	The effects of chronic kidney disease and renal replacement therapy on circulating dendritic cells. *Nephrology Dialysis Transplantation*, **2005**, 20, 1868-73	4.3	44
34	Functional heme oxygenase-1 promoter polymorphism in relation to heart failure and cardiac transplantation. *Journal of Heart and Lung Transplantation*, **2005**, 24, 493-7	5.8	14
33	The beneficial effects of recipient-derived vascular endothelial growth factor on graft survival after kidney transplantation. *Transplantation*, **2005**, 79, 1221-5	1.8	19
32	Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. *Transplantation*, **2005**, 80, 110-7	1.8	184
31	Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. *Hepatology*, **2005**, 41, 771-8	11.2	404
30	Tapering immunosuppression in recipients of living donor kidney transplants. *Nephrology Dialysis Transplantation*, **2004**, 19 Suppl 4, iv61-3	4.3	15
29	Fundamental role for HO-1 in the self-protection of renal allografts. *American Journal of Transplantation*, **2004**, 4, 811-8	8.7	70
28	Clinical impact of cytokine gene polymorphisms in heart and lung transplantation. *Journal of Heart and Lung Transplantation*, **2004**, 23, 1017-26	5.8	26
27	Apoptotic death of infiltrating cells in human cardiac allografts is regulated by IL-2, FASL, and FLIP. *Transplantation Proceedings*, **2004**, 36, 3143-8	1.1	9
26	Intragraft heme oxygenase-1 and coronary artery disease after heart transplantation. *Transplant Immunology*, **2004**, 13, 265-72	1.7	9
25	Living kidney donors and hypoxia-inducible factor-1alpha. *Transplantation*, **2003**, 75, 570-1	1.8	17
24	Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation. *Transplantation*, **2003**, 75, 1704-10	1.8	21

23	Differential intragraft cytokine messenger RNA profiles during rejection and repair of clinical heart transplants. A longitudinal study. *Transplant International*, **2003**, 16, 9-14	3	15
22	Differential expression of heme oxygenase-1 and vascular endothelial growth factor in cadaveric and living donor kidneys after ischemia-reperfusion. *Journal of the American Society of Nephrology: JASN*, **2003**, 14, 3278-87	12.7	67
21	Differential intragraft cytokine messenger RNA profiles during rejection and repair of clinical heart transplants. A longitudinal study. *Transplant International*, **2003**, 16, 9-14	3	4
20	Prediction of mortality in heart transplant recipients by stress technetium-99m tetrofosmin myocardial perfusion imaging. *American Journal of Cardiology*, **2002**, 89, 964-8	3	38
19	Sequential monitoring of intragraft cytokine mRNA expression in relation to diastolic left ventricular wall thickness and function early after heart transplantation. *Clinical Transplantation*, **2002**, 16, 433-41	3.8	6
18	Effect of HLA-DR matching on acute rejection after clinical heart transplantation might be influenced by an IL-2 gene polymorphism. *Transplantation*, **2002**, 73, 1353-6	1.8	10
17	T cells activate the tumor necrosis factor-alpha system during hemodialysis, resulting in tachyphylaxis. *Kidney International*, **2001**, 59, 883-92	9.9	20
16	Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-beta 1 type I receptor expression. *Clinical Transplantation*, **2001**, 15, 276-83	3.8	21
15	Quantitative flow cytometry shows activation of the TNF-alpha system but not of the IL-2 system at the single cell level in renal replacement therapy. *Nephrology Dialysis Transplantation*, **2001**, 16, 1430-5	4.3	12
14	Failure to down-regulate intragraft cytokine mRNA expression shortly after clinical heart transplantation is associated with high incidence of acute rejection. *Journal of Heart and Lung Transplantation*, **2001**, 20, 503-10	5.8	11
13	The transforming growth factor-beta1 codon 10 gene polymorphism and accelerated graft vascular disease after clinical heart transplantation. *Transplantation*, **2001**, 71, 1463-7	1.8	47
12	Two doses of daclizumab are sufficient for prolonged interleukin-2Ralpha chain blockade. *Transplantation*, **2001**, 72, 1709-10	1.8	20
11	Renal failure after clinical heart transplantation is associated with the TGF-beta 1 codon 10 gene polymorphism. *Journal of Heart and Lung Transplantation*, **2000**, 19, 866-72	5.8	59
10	Functional responses of T cells blocked by anti-CD25 antibody therapy during cardiac rejection. *Transplantation*, **2000**, 69, 331-6	1.8	21
9	Intragraft platelet-derived growth factor-alpha and transforming growth factor-beta1 during the development of accelerated graft vascular disease after clinical heart transplantation. *Transplant Immunology*, **1999**, 7, 201-5	1.7	7
8	Anti-CD25 therapy reveals the redundancy of the intragraft cytokine network after clinical heart transplantation. *Transplantation*, **1999**, 67, 870-6	1.8	40
7	Intragraft cytokine gene expression: implications for clinical transplantation. *Transplant International*, **1998**, 11, 169-180	3	39
6	Intragraft cytokine gene expression: implications for clinical transplantation. *Transplant International*, **1998**, 11, 169-80	3	6

5	Kinetics of IL-2 and IL-4 mRNA and protein production by graft-infiltrating lymphocytes responsible for rejection after clinical heart transplantation. *Transplant Immunology*, **1997**, 5, 97-103	1.7	6
4	Characteristics of graft-infiltrating lymphocytes after human heart transplantation. HLA mismatches and the cellular immune response within the transplanted heart. *Human Immunology*, **1994**, 39, 233-42	2.3	7
3	The detection of cytotoxic T cells with high-affinity receptors for donor antigens in the transplanted heart as a prognostic factor for graft rejection. *Transplantation*, **1993**, 56, 1223-9	1.8	41
2	Altered specificity of alloreactive cardiac graft-infiltrating cells by prophylactic treatment with OKT3 or horse antilymphocyte globulin. *Transplantation*, **1993**, 55, 154-8	1.8	3
1	Rejection of a kidney graft mismatched only for the HLA-C locus and an HLA-BW22 split. *Transplantation*, **1993**, 55, 438-9	1.8	19